A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19
Latest Information Update: 13 Sep 2023
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications COVID 2019 infections; Post acute COVID 19 syndrome
- Focus Registrational; Therapeutic Use
- Acronyms SPRINTER
- Sponsors Synairgen
- 24 May 2023 Results presented at the 119th International Conference of the American Thoracic Society
- 23 Jan 2023 According to a Synairgen media release, Phillip Monk is the lead author of the ERJOR publication.
- 23 Dec 2022 According to a Synairgen media release, the company announced the online publication of data from the study in the peer reviewed European Respiratory Journal Open Research (ERJOR).